RNAZ - Why Is Brain Cancer Focused TransCode Therapeutics Stock Trading 300% Higher Today? | Benzinga
TransCode Therapeutics Inc (NASDAQ: RNAZ) shares are trading higher after the company announced results with its lead therapeutic candidate, TTX-MC138, in murine models bearing human glioblastoma multiforme (GBM) tumors.
In this study, the therapeutic candidate was delivered to brain tumors and effectively engaged its target.
In the study reported by TransCode, mice implanted with tumors derived from human GBM patients were treated with TTX-MC138 and imaged by magnetic resonance imaging ...